AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) went up by 2.94% from its latest closing price compared to the recent 1-year high of $18.24. The company’s stock price has collected -4.23% of loss in the last five trading sessions. Press Release reported on 03/29/21 that Thinking about buying stock in Super League Gaming, Welbilt, Oramed Pharmaceuticals, AVEO Pharmaceuticals, or Oncolytics Biotech?
Is It Worth Investing in AVEO Pharmaceuticals Inc. (NASDAQ :AVEO) Right Now?
Plus, the 36-month beta value for AVEO is at 1.26. Opinions of the stock are interesting as 3 analysts out of 4 who provided ratings for AVEO Pharmaceuticals Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $22.75. AVEO currently public float of 23.91M and currently shorts hold a 9.21% ratio of that float. Today, the average trading volume of AVEO was 2.57M shares.
AVEO’s Market Performance
AVEO stocks went down by -4.23% for the week, with a monthly drop of -13.24% and a quarterly performance of 11.09%, while its annual performance rate touched 93.11%. The volatility ratio for the week stands at 5.89% while the volatility levels for the past 30 days are set at 15.13% for AVEO Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -25.01% for AVEO stocks with a simple moving average of 9.94% for the last 200 days.
Analysts’ Opinion of AVEO
Many brokerage firms have already submitted their reports for AVEO stocks, with Stifel repeating the rating for AVEO by listing it as a “Buy.” The predicted price for AVEO in the upcoming period, according to Stifel is $9 based on the research report published on November 09th of the previous year 2020.
SVB Leerink, on the other hand, stated in their research note that they expect to see AVEO reach a price target of $7. The rating they have provided for AVEO stocks is “Outperform” according to the report published on August 13th, 2020.
H.C. Wainwright gave a rating of “Buy” to AVEO, setting the target price at $1.75 in the report published on September 11th of the previous year.
AVEO Trading at -20.29% from the 50-Day Moving Average
After a stumble in the market that brought AVEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.57% of loss for the given period.
Volatility was left at 15.13%, however, over the last 30 days, the volatility rate increased by 5.89%, as shares sank -54.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.20% lower at present.
During the last 5 trading sessions, AVEO fell by -4.23%, which changed the moving average for the period of 200-days by +32.02% in comparison to the 20-day moving average, which settled at $8.93. In addition, AVEO Pharmaceuticals Inc. saw 21.49% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at AVEO starting from SANDELL SCOTT D, who purchase 1,428,571 shares at the price of $5.25 back on Jun 19. After this action, SANDELL SCOTT D now owns 3,952,958 shares of AVEO Pharmaceuticals Inc., valued at $7,499,998 using the latest closing price.
Sonsini Peter W., the 10% Owner of AVEO Pharmaceuticals Inc., purchase 1,428,571 shares at $5.25 during a trade that took place back on Jun 19, which means that Sonsini Peter W. is holding 3,952,958 shares at $7,499,998 based on the most recent closing price.
Stock Fundamentals for AVEO
Current profitability levels for the company are sitting at:
- -645.90 for the present operating margin
The net margin for AVEO Pharmaceuticals Inc. stands at -591.19. The total capital return value is set at -96.73, while invested capital returns managed to touch -102.56. Equity return is now at value -109.00, with -56.00 for asset returns.
Based on AVEO Pharmaceuticals Inc. (AVEO), the company’s capital structure generated 41.02 points at debt to equity in total, while total debt to capital is 29.09. Total debt to assets is 21.64, with long-term debt to equity ratio resting at 36.98. Finally, the long-term debt to capital ratio is 26.22.
When we switch over and look at the enterprise to sales, we see a ratio of 12.66, with the company’s debt to enterprise value settled at 0.19. The receivables turnover for the company is 4.26 and the total asset turnover is 0.10. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.87.